NCT04759911View on ClinicalTrials.gov

Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 26, 2021

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Malignant Thyroid Gland NeoplasmPoorly Differentiated Thyroid Gland CarcinomaRecurrent Thyroid Gland CarcinomaThyroid Gland Anaplastic CarcinomaThyroid Gland Medullary CarcinomaThyroid Gland Papillary CarcinomaThyroid Gland Squamous Cell Carcinoma
Interventions
OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Selpercatinib

Given PO

PROCEDURE

Therapeutic Conventional Surgery

Undergo standard of care surgery

Trial Locations (3)

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

48109

University of Michigan Health Systems, Ann Arbor

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER